About wpteam

This author has not yet filled in any details.
So far wpteam has created 30 blog entries.

January 2023

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma

By |2023-01-25T00:56:39+00:00January 25th, 2023|

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma Haddonfield NJ, January 19, 2023--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. [...]

Read More

September 2022

Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office

By |2022-09-27T18:05:10+00:00September 27th, 2022|

Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office Haddonfield NJ, September 21, 2022 - Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that [...]

Read More

Linnaeus Therapeutics Announces Presentation of LNS8801 Clinical Data at 2022 ESMO Annual Meeting

By |2022-09-27T18:00:44+00:00September 27th, 2022|

Linnaeus Therapeutics Announces Presentation of LNS8801 Clinical Data at 2022 ESMO Annual Meeting Haddonfield NJ, September 12, 2022 - Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of clinical biomarker [...]

Read More

June 2022

Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting

By |2022-06-09T18:57:27+00:00June 9th, 2022|

Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 at 2022 ASCO Annual Meeting Haddonfield NJ, June 6, 2022 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation [...]

Read More

April 2022

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma

By |2022-04-11T14:39:13+00:00April 11th, 2022|

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma Haddonfield NJ, April 6, 2022 -- Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization [...]

Read More

June 2021

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer

By |2021-06-16T10:15:45+00:00June 16th, 2021|

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer Studies Will be Conducted at Multiple NCI-Designated Comprehensive Cancer Centers Haddonfield NJ, June 15, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical [...]

Read More

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting

By |2021-06-08T10:31:47+00:00June 8th, 2021|

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting Haddonfield NJ, June 7, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced the presentation of [...]

Read More

March 2021

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office

By |2021-03-10T14:59:51+00:00March 10th, 2021|

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office US Patent 10,934,277 Issued on March 2, 2021 Haddonfield NJ, March 10, 2021-- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and [...]

Read More

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma

By |2021-03-10T14:50:51+00:00March 10th, 2021|

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma Haddonfield NJ, March 10, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. [...]

Read More

October 2020

Linnaeus Therapeutics Announces First Patient Dosed in Its Clinical Trial of LNS8801 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Cancer

By |2020-10-16T14:58:12+00:00October 16th, 2020|

Company Commences Phase 2 Study at Multiple Academic Sites in United States Haddonfield NJ, October 13, 2020--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first [...]

Read More
© Copyright 2012 -    |   ALL RIGHTS RESERVED